Heron Therapeutics | HRTX - Sales Revenues


Heron Therapeutics reported $40.59M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
ALKERMES USD 496.01M 103.1M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amarin USD 49.22M 451K Dec/2025
ANI Pharmaceuticals USD 266M 28.5M Jun/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 75.23M 1.49M Jun/2026
Eisai JPY 234.33B 28.9B Jun/2026
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 425.49M 119.53M Jun/2026
Ligand Pharmaceuticals USD 83.7M 31.98M Jun/2026
Merck USD 16.6B 310M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Pacira USD 192.4M 15.4M Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Veracyte USD 150.32M 11.25M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026